Cellectis (CLLS) Stock Price, News & Analysis

Company Overview

Cellectis S.A. is a clinical-stage biopharmaceutical company specializing in allogeneic chimeric antigen receptor T-cell (CAR-T) therapies engineered with its proprietary TALEN® gene-editing technology. The company focuses on developing off-the-shelf cellular immunotherapies designed to target hematologic malignancies and solid tumors. By using donor-derived T cells, Cellectis aims to streamline manufacturing processes and deliver treatments more rapidly than traditional autologous approaches.

Founded in 1999 and headquartered in Paris, France, Cellectis has built a comprehensive research and development platform that integrates gene editing, cell line engineering, and process development. The company entered the Nasdaq market in 2015, marking a pivotal step in its growth strategy. Under the leadership of founder and CEO Dr. André Choulika, Cellectis has expanded its TALEN technology repertoire and established partnerships to enhance clinical translational capabilities.

Beyond its Paris headquarters, Cellectis maintains research sites in New York and operates GMP-compliant manufacturing facilities across Europe and the United States. Its global clinical pipeline includes multiple allogeneic CAR-T candidates targeting indications such as acute lymphoblastic leukemia, non-Hodgkin lymphoma, and select solid tumors. Collaborative agreements with pharmaceutical companies and academic centers support the company’s efforts to explore novel targets and combination regimens.

Looking forward, Cellectis is advancing pivotal clinical trials for its lead candidates while investing in next-generation gene-editing solutions to improve safety profiles and therapeutic efficacy. With a growing footprint in major markets and a commitment to innovation, the company is strategically positioned to address unmet needs in oncology and drive the broader adoption of allogeneic cell therapies.

Key Stats

• Today's Range: $1.85 to $1.95
• 50-Day Range: $1.33 to $2.15
• 52-Week Range: $1.10 to $2.43
• Volume: 43,674 shs
• Average Volume: 149,380 shs
• Market Capitalization: $107.27 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Buy

Cellectis Stock Analysis - MarketRank™

Cellectis scored higher than 69% of companies evaluated by MarketBeat, and ranked 335th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Cellectis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Cellectis has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Cellectis are expected to decrease in the coming year, from ($0.46) to ($0.52) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cellectis is -2.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cellectis is -2.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cellectis has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.44% of the float of Cellectis has been sold short.

Short Interest Ratio / Days to Cover

Cellectis has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cellectis has recently decreased by 4.07%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cellectis does not currently pay a dividend.

Dividend Growth

Cellectis does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.44% of the float of Cellectis has been sold short.

Short Interest Ratio / Days to Cover

Cellectis has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cellectis has recently decreased by 4.07%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

Cellectis has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Medical companies.

Search Interest

3 people have searched for CLLS on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Cellectis to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cellectis insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.41% of the stock of Cellectis is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

63.90% of the stock of Cellectis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CLLS Stock Analysis - Frequently Asked Questions

How have CLLS shares performed this year?

Cellectis' stock was trading at $1.80 at the beginning of 2025. Since then, CLLS stock has increased by 7.2% and is now trading at $1.93.

How were Cellectis' earnings last quarter?

Cellectis S.A. (NASDAQ:CLLS) issued its earnings results on Monday, May, 12th. The biotechnology company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.03. The biotechnology company earned $12.03 million during the quarter, compared to the consensus estimate of $12.71 million. Cellectis had a negative trailing twelve-month return on equity of 62.55% and a negative net margin of 114.82%.

When did Cellectis IPO?

Cellectis (CLLS) raised $129 million in an IPO on Wednesday, March 25th 2015. The company issued 3,500,000 shares at $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer was co-manager.

How do I buy shares of Cellectis?

Shares of CLLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cellectis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cellectis investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU) and Alibaba Group (BABA).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CLLS
• CIK: 1627281
• Web: www.cellectis.com
• Phone: (318) 169-1600
• Fax: 33-1-81-69-16-06
• Employees: 290
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Cellectis: $4.00
• High Price Target: $4.00
• Low Price Target: $4.00
• Potential Upside/Downside: +107.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.86)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$36.76 million
• Net Margins: -114.82%
• Pretax Margin: -82.79%
• Return on Equity: -62.55%
• Return on Assets: -21.19%

Debt

• Debt-to-Equity Ratio: 0.44
• Current Ratio: 1.67
• Quick Ratio: 1.67

Sales & Book Value

• Annual Sales: $49.22 million
• Price / Sales: 2.18
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.36 per share
• Price / Book: 0.82

Miscellaneous

• Outstanding Shares: 55,580,000
• Free Float: 46,463,000
• Market Cap: $107.27 million
• Optionable: Optionable
• Beta: 2.91